The forecast for antiarrhythmic medicine sales in Germany indicates a stable market with a per capita expenditure of $0.8 from 2024 to 2028. This reflects no growth or decline in year-on-year variations. As of 2023, the sales value stood at $0.8 per capita, and projections maintain this level without significant change. The Compound Annual Growth Rate (CAGR) over the previous five years is 0%, suggesting a plateau in sales volumes and market dynamics.
Future trends to watch for include:
- Potential advancements in alternative treatments that could impact market stability.
- Regulatory developments affecting the pharmaceutical sector in Germany.
- Health policy changes potentially increasing demand for cardiological treatments.
